Lower risk of side effects compared to synthetic GH therapy
This makes blood sugar levels harder to control, and many people need more medications to keep their blood sugars in their target range
Abstract Sodium-glucose cotransporters inhibitors (SGLT2-i) and GLP-1 receptor agonists (GLP1-RA) are glucose-lowering drugs that are proved to reduce the cardiovascular (CV) risk in type 2 diabetes mellitus (T2DM)
External resources For researchers serious about understanding the full landscape of weight loss medications and making informed decisions about peptide-based treatments, SeekPeptides provides the most comprehensive resource available, with evidence-based guides, detailed comparison tools, and a community of thousands who have navigated these exact questions
Regulatory note: Health Canada is warning consumers about the serious health risks of unapproved peptides
When using the semaglutide pen either Ozempic or Wegovy, women may have questions about dosages, injection technique, proper injection site rotation, or possible side effects